Dehao Health (000813.SZ) affiliated company's research product VGX-3100 clinical trial unblinding achieves the pre-set primary efficacy endpoint.

Flush financial and economic APP news, Dezheng Health (000813.SZ) announced that its affiliated company Beijing Dongfang Luey Biomedical Technology Co., Ltd. (hereinafter referred to as "Dongfang Luey") has unblinded the pivotal Phase III registration clinical trial of VGX-3100 in China and achieved positive top-line results, meeting the pre-specified primary efficacy endpoint.